MSH2 and cancer: By focusing on LSVH with variants in the MLH1 and MSH2 genes, as well as a unique and large cohort of LSVH with an MLH1 founder variant in South Africa, this work brings to light gene- and sex-specific cancer risks and survival patterns previously unreported in the literature, offering invaluable data for tailoring LS management in underrepresented populations.